

#### **PATENT**

# In the UNITED STATES PATENT and TRADEMARK OFFICE

Auestad, et al

**SERIAL NO.:** 

10/602,169

FILED:

June 24, 2003

TITLE:

APPETITE CONTROL METHOD

**EXAMINER:** Not yet assigned ART UNIT: Not yet assigned DOCKET NO.: 6960.US.01

I certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, Alexandria, VA, on the date shown below.

Wendy Detwiler

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Enclosed herewith is a Information Disclosure Statement and Form 1449 for the above-referenced patent application. Also enclosed are:

Sixty-four (64) references One (1) return postcard

If any fees are owed, or any credit is due pertaining to this case; please charge that fee or apply that credit to Deposit Account No. 01-0025.

Respectfully submitted,

Ross Products Division of ABBOTT LABORATORIES Department 108140/DS1 625 Cleveland Avenue Columbus, OHIO 43215-1724

Telephone: 614/624-5686

Facsimile:

614/624-3074

Docket: 6960.US.01

by William J. Winter Reg. No. 36,060



In the UNITED STATES PATENT and TRADEMARK OFFICE

APPLICANT: Auestad, et al.

SERIAL NO.: 10/602,169

FILING DATE: June 24, 2003

TITLE: APPETITE CONTROL METHOD

Not yet assigned EXAMINER: ART UNIT: Not yet assigned DOCKET NO.: 6960.US.01

I certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, Alexandria, VA 22313-1450

on the date shown below

Wendy Detwiter

Date

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

#### Dear Sir:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, and as authorized and encouraged under 37 C.F.R. §§ 1.97-1.98 and the provisions of MPEP §§ 609 and 707.05(b), Applicants submit herewith certain patent documents, publications and/or other information ("references") which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. The identification of any reference herein is not intended to be and should not be understood as being an admission that such reference necessarily constitutes "prior art" within the meaning of applicable law.

The cited references are listed on attached form PTO-1449.

- A copy of each cited reference is provided; X
- Copies of cited references are not provided because each has previously been made of record in the parent application, or is otherwise known to be in the Examiner's possession.

The Examiner is requested to review and evaluate each cited reference to make an independent assessment of the materiality of each, if any, to the examination of the aboveidentified application. The Examiner is requested to ignore any underscoring or highlighting which may have been done because such markings may or may not have any relationship to the subject matter of the present invention. The copies being submitted with this Statement are the best copies available at this time. Applicants respectfully request that (1) the references cited herein be made of record; (2) that the Examiner acknowledge his consideration of each reference by initialing and returning the enclosed copy of the PTO-1449 form; and (3) that such references appear on the printed patent as having been considered on the record.

With regard	to pa	yment of a fee:
	×	No fee is due because:
	X	This Statement is mailed within three months of the filing date of this application, or before the mailing date of a first office action on the merits (see 37 C.F.R. §1.97(b)).
		Applicants certify that each reference cited in this Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. (see 37 C.F.R. §1.97(e)).
		This Statement is filed after the mailing date of a first Office Action on the merits but before the mailing date of either a

If any fees are owed, or any credit is due pertaining to this case, please charge that fee or apply that credit to Deposit Account No. 01-0025. A duplicate sheet of this page is enclosed.

final action or a Notice of Allowance (see 37 C.F.R. §1.97(c)) so a fee of \$180.00 is specified by 37 C.F.R. §1.17(p).

Ross Products Division of ABBOTT LABORATORIES Dept. 108140-DS/1 625 Cleveland Avenue Columbus, OHIO 43215-1724

Telephone: (614) 624-5686 Facsimile: (614) 624-3074

Docket: 6960.US.01

Respectfully submitted,

William J. Winter Reg. No. 36,060

Sheet 1 of 6

FØRM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6960.US.01	Serial No. 10/602,169
, <u>, , , , , , , , , , , , , , , , , , </u>	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Auestad, et al.	
	(Use several sheets if necessary)	Filing Date June 24, 2003	Group

**U.S. PATENT DOCUMENTS** 

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
					<del> </del>	

**FOREIGN PATENT DOCUMENTS** 

Document Number	Date	Name	Class	Subclass	Translation (Yes No)
		l			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ameri A. The effects of cannabinoids on the brain. Progress in Neurobiology, 58:315-348, (1999).
	Arbuckle LD and Innis SM. Docosahexaenoic acid is transferred through maternal diet to milk and to tissues of natural milk-fed piglets. J Nutr, 123(10): 1668-11675, (1993).
	Auestad N, Korsak RA, Bergstrom JD, and Edmond J. Milk-substitutes comparable to rat's milk; their preparation, composition, and impact on development and metabolism in the artificially reared rat. British Journal of Nutrition, 61: 495-518, (1989).
	Barinaga M. Pot, heroin unlock new areas for neuroscience. Science, 258:1882-1884, (1992).
	Berger A, Crozier G, Bisogno T, Cavaliere, Innis S, and Di Marzo V. Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. PNAS, 98(11): 6402-6406, (2001).
	Berthoud H-R. An overview of neural pathways and networks involved in the control of food intake and selection. In: Neural and Metabolic Control of Macronutrient Intake (H-R Berthoud and RJ Seeley, Eds). CRC Press, Boca Raton, FL. Chapter 24: 361-387, (2000).
	Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, and Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochemical and Biophysical Research Communications, 256: 377-380, (1999).
	Buckley NE, Hansson S, Harta G, and Mezey E. Expression of the CB₁ and CB₂ receptor messenger RNAs during embryonic development in the rat. Neuroscience, 82(4): 1131-1149, (1998).
	Centers for Disease Control and Prevention. Obesity and Overweight: Basics about overweight and obesity. <a href="http://www.cdc.gov/nccdphp/dnpa/obesity/basics.htm">http://www.cdc.gov/nccdphp/dnpa/obesity/basics.htm</a> (2002)
EXAMIN	

Sheet 2 of\_ Atty. Docket No. Serial No. FORM PTO-1449 U.S. Department of Commerce 6960.US.01 10/602,169 Patent and Trademark Office Applicant INFORMATION DISCLOSURE STATEMENT BY APPLICANT Auestad, et al. Filing Date Group (Use several sheets if necessary) June 24, 2003 **U.S. PATENT DOCUMENTS** Subclass Filing Date (if appro.) Class Examiner Document Number Date Name Initial **FOREIGN PATENT DOCUMENTS** Class Subclass Translation (Yes No) Document Number Name OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Chaperon F and Thiebot M-H. Behavioral effects of cannabinoid agents in animals. Critical Reviews in Neurobiology, 13(3): 243-281, (1999). de la Presa Owens S and Innis SM. Docosahexaenoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and  $\alpha$ -linolenic acid deficient diet in formula-fed piglets. Journal of Nutrition, 129: 2088-2093, (1999). de la Presa Owens S and Innis SM. Diverse, region-specific effects of addition of arachidonic and doxosahexanoic acids to formula with low or adequate linoleic and  $\alpha$ linolenic acids on piglet brain monoaminergic neurotransmitters. Pediatric Research. 48: 125-130, (2000). Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258: 1946-1949, (1992). DiMarzo V, DePetrcellis L, Bisogno T, and Melck D. Metabolism of anandamide and 2arachidonovlolvcerol: an historical overview and and some recent developments. Lipids, 34:S319-S325, (1999). DiMarzo V, Goparaju SK, Wang L, Liu J, Batkal S, Jaral Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410:822-825, (2001). Farquharson J, Jamieson EC, Abbasi KA, Patrick WJ, Logan RW, and Cockburn F. Effect of diet on the fatty acid composition of the major phospholipids of infant cerebral cortex. Arch Dis Child, 72(3): 198-203, (1995). Felder CC, Briley EM, Axelrod J, Simpsom JT, Mackie K, and Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl, Acad. Sci., 90:7656-7660, (1993). Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Folch J, Lees M, and Sloane-Stanley GA. J. Biol. Chem. 226:497, (1957).

Fontana A, Di Marzo V, Cadas H, and Piomelli D. Analysis of anandamide, an endogenous cannabinoid substance, and of other natural *N*-acylethanolamines. Prostaglandins Leukotrienes and Essential Fatty Acids, 53:301-308, (1995).

human and rat. FEBS Letters, 393:231-235, (1996).

**EXAMINER** 

SEP 7 3 2003

Sheet 3 of 6

FORM PTO-1449 U.S. Department of Commerce (Rev. 2032) Patent and Trademark Office 6960.US.01 10/602,169

INFORMATION DISCLOSURE Applicant Auestad, et al.

(Use several sheets if necessary) Filing Date Group

		se severai siii		,		June 24, 20	03	<u> </u>	
U.S Examiner	Document Numb		Date	Name	Subclass Filing Date (if		e (if appro.)		
nitial	Document Numb	,,,,	Date		Class		1		
				_			-	·····	
						<del> </del>	<del> </del>		
	DEION DATEN	T DOCUMEN	ITC			.1	.l		
FU	REIGN PATEN  Document Numb		Date	Name	Class	Subclass	Translatio	n (Yes No)	
	Doddinginerrains	-					<u> </u>		
						<del> </del>	<del></del>		
01	HED DOCUME	NTS (Includ	ing Autho	r, Title, Date, Pe	rtinent Pages.	Etc.)			
<del>- 1 01</del>	Fride	F Ginzhur	Y Breue	er A, Bisogno T	Di Marzo V.	Mechoulam	R. Critical	role of the	
	endo	genous can	nabinoid	system in mous	e pup suckling	and growth	. Europea	an Journal	
İ		macology, 4							
	Gaon	i Y and Med	houlam F	R. Isolation, str	ucture and par	rtial synthesi	is of an ac	tive	
	const	tituent of ha	shish. J.	Am. Chem. Soc	:. 86:1646 (19	964).			
				Molecular cha			d mouse fa	atty acid	
	amide	e hydrolase	s. Proc. N	Vatl. Acad. Sci.	94:2238-224	2, (1997). <u> </u>		-1' -1'	
1				nd Piomelli D.				ictivation:	
				cology. Journal	or Pharmacor	ogy and Ext	ennena		
	Conc	apeutics, 29	o(1). 7-14	maguchi H, and	Vamamoto S	Anandami	de amidot	vdrolase	
	react	ing with 2-a	rachidone	ylglycerol, and	her cannabing	oid receptor	licand. FE	BS Letters	
		69-73, (1998		yigiyooroi, ano		,			
	Guzn	man M and S	Sanchez (	C. Effects of ca	nnabinoids or	energy met	abolism.	Life	
	Scier	nces, 65 (6/	7):657-66	4, (1999).					
	Hanu	ıs L, Gophe	A, Almo	g S, and Mecho	ulam R. Two	new unsatu	rated fatty	acid	
	ethar	nolamides ir	brain tha	at bind to the ca	nnabinoid rec	eptor. J Me	d. Chem.,	36:3032-	
	3034	, (1993).							
	Hao	S, Avraham	Y, Mecho	oulam, and Ber	y EM. Low do	ose anandar	nide affect	(S 1000	
ļ	intak	e, cognitive	tunction,	neurotransmitte	er and corticos	e (2000)	S III GIEC-IE	Suicieu	
	mice	European	Journal C	of Pharmacolog and Boutelle KN	y, 392.147-13	onds in ana	rov intake	in the Unite	
ı	Ham	iack LJ, Jeli se: an ecolo	ncical ner	spective. An J	Clin Nutr 71:1	478-1484. (	2000).		
-+-	Have	P. Perin	heral sign	als conveying i	netabolic infor	mation to th	e brain: s	hort-term a	
	long-	-term regula	tion of for	od intake and e	nergy homeos	tatis. Exp B	io Med, 22	26 (11): 963	
	977.	(2001).							
	Heiro	d WC. Pare	ntal feedi	ng behavior an	d children's fa	t mass. Am	J Clin Nut	r, 75:451-	
	452,	(2002).							
	Hilla	rd CJ. Bioc	hemistry	and pharmacol	gy of the end	ocannabinoi	ds	1 !! -!	
1				and 2-arachido	nylglycerol. P	rostaglandir	ns and oth	er Lipid	
		iators, 61:3-	18, (2000	)). DATE CON	CIDEDED				
1	EXAMINER		1	DATE CON	SIDENED				

2 3 2003 Sheet 4 of Atty. Docket No. Serial No. FORW PTO-1449 **U.S. Department of Commerce** 6960.US.01 10/602,169 Patent and Trademark Office Applicant INFORMATION DISCLOSURE STATEMENT BY APPLICANT Auestad, et al. Filing Date Group (Use several sheets if necessary) June 24, 2003 **U.S. PATENT DOCUMENTS** Filing Date (if appro.) Class Subclass Examiner Document Number Date Name Initiat FOREIGN PATENT DOCUMENTS Class Subclass Translation (Yes No) Document Number Name OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Kaiyala KJ, Woods SC, and Schwartz MW. New model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 62 (suppl): 1223S-1234S, (1995). Kempe K, Hsu-F-F, Bohrer A, and Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamine, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. Journal of Biological Chemistry, 271 (29): 17287-17295, (1996). Kirkham TC, Williams CM, Fezza F, and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding, and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136:550-557, (2002). Kondo S, Kondo H, Nakane S, Kodaka T, Tokumura A, Waku K, and Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species on monoacylglycerols in various rat tissues, and evidence for its generation through Ca2+-dependent and -independent mechanisms. FEBS Letters, 429: 152-156, (1998). Liu J, Lee T, Bobik, Jr. E, Guzman-Harty M, and Hastilow C. Quantitative Determination of Monoglycerides and Diglycerides by High-Performance Liquid Chromatography and Evaporative Light-Scattering Detection. Journal of the American Oil Chemists' Society, 70(4):343-347, (1993). Makrides M, Neumann MA, Byrad RW, Simmer K, and Gibson RA. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J. Clin Nutr. 60(2):189-194, (1994). McLaughlin CR, Martin BR, Compton DR, and Abood ME. Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug and Alcohol Dependence, 36:27-31, (1994). Mechoulam R, Ben-Shabat S, Hanus L, Ligumski L, Kaminshi NE, Schatz AR, Gopher A, Amlog S, Martin BR, and Comton DR. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol, 50:83-90, (1995).Mechoulam R and Fride E. A hunger for cannabinoids. Nature, 410:763-764, (2001). Mechoulam R, Fride E, and Di Marzo V. Endocannabinoids. European Journal of Pharmacology, 359:1-18, (1998) DATE CONSIDERED **EXAMINER** 

Sheet 5 of\_ Atty. Docket No. Serial No. FORM PTO-1449 U.S. Department of Commerce 6960.US.01 10/602,169 (Rey. 2032) Patent and Trademark Office INFORMATION DISCLOSURE **Applicant** STATEMENT BY APPLICANT Auestad, et al. (Use several sheets if necessary) Filing Date Group June 24, 2003 U.S. PATENT DOCUMENTS Subclass Filing Date (if appro.) Class Examiner **Document Number** Date Name Initial **FOREIGN PATENT DOCUMENTS** Document Number Name Class Subclass Translation (Yes No) OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Muller MJ, Koertringer I, Mast M, Languix, and Frunch A. Physical activity and diet in 5 to 7 years old children. Public Health Nutrition, 2(3a):443-444. (1999). Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, and Uhl GR. Endocannabinoids and cannabinoid receptor genetics. Progress in Neurobiology, 66:307-Onis M de and Blossner M. Prevalence and trends of overweight among preschool children in developing countries.. Am J Clin Nutr, 72:1032-1039, (2000). Patricelli MP and Cravatt BF. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amindes. Vitamins and Hormones, 62:95-131, (2001). Reeves PG, Nielsen FH, and Fahey GC, Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. Journal of Nutrition, 123:1939-1951, (1993). Salzet M, Breton C, Bisogno T, and Di Marzo V. Comparative biology of the endocannabinoid system—possible role in the immune response. Eur J Biochem, 267:4917-4927. (2000). Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, and Schmid HHO. Occurrence and postmortem generation of anandamide and other long-chain Nacylethanolamines in mammalian brain. FEBS Letters, 375:117-120, (1995). Schmid PC, Schwartz KD, Smith CN, Krebsbach RJ, Berdyshev EV, and Schmid HHO. A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chemistry and Physics of Lipids, 104:185-191, (2000). Schneider D. International trends in adolescent nutrition. Social Science & Medicine, 51:955-967 (2000). Smart JL, Stephens DN, and Katz HB. Growth and development of rats artificially reared on a high or a low plane of nutrition. British Journal of Nutrition, 49: 497-506, (1983). Smart JL. Stephens DN, Tonkiss J, Auestad NS, and Edmond J. Growth and development of rats artificially reared on different milk-substitutes. British Journal of

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sonnenberg N, Bergstrom JD, Ha YH, and Edmond J. Metabolism in the artificially reared rat pup: effect of an atypical rat milk substitute. Journal of Nutrition, 112: 1506-1514,

Spruijt-Metz D, Lindquist CH, Birch LL, Fisher JO, and Goran MI. Relation between mothers' child-feeding practices and children's adiposity. Am J Clin Nutr, 75:581-586,

DATE CONSIDERED

Nutrition, 52: 227-237, (1984).

(2002).

**EXAMINER** 

SEP 2 3 2003 Sheet 6 of <u>6</u> U.S. Department of Commerce Atty. Docket No. Serial No. FORM PTO-1449 6960.US.01 10/602,169 Rév. 2032) Patent and Trademark Office Applicant INFORMATION DISCLOSURE STATEMENT BY APPLICANT Auestad, et al. Filing Date Group (Use several sheets if necessary) June 24, 2003 **U.S. PATENT DOCUMENTS** Class Subclass Filing Date (if appro.) Examiner Document Number Date Name Initial **FOREIGN PATENT DOCUMENTS** Name Class Subclass Translation (Yes No) Document Number OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Sugiura T, Kodaka T, Nakane S, Kishimoto A, Konda S, and Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid ligand in brain. Biochem. Biophys. Res. Commun, 215:89-97, (1995). Sugiura T and Waku K. 2-Arachidonylglycerol: a possible multifunctional lipid mediator in the nervous and immune systems. Annals New York Academy of Sciences, VOL: 344-346, (2000). Van Diik G. Chavez M. Reidy CA, and Woods SC. Adiposity signals and macronutrient selection. In: Neural and Metabolic Control of Macronutrient Intake. (H-R Berthoud and RJ Seeley, Eds). CRC Press, Boca Raton, FL. Chapter 30: 465-472, (2000). Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M, Shimizu H, Matsuo S. Imaizumi H, and Maruyama I. Simultaneous measurement of anandamide and 2arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Analytical Biochemistry, 294:73-82, (2001) Ward GR, Huang YS, Bobik E, Xing H-C, Mutsaers L, Auestad N, Montalto M, and Wainwright P. Long-chain polyunsaturated fatty acid levels in formulae influence deposition of docosahexaenoic acid and arachidonic acid in brain and red blood cells of artificially reared neonatal rats. Journal of Nutrition, 128: 2473-2487, (1998). Ward GR, Huang Y-S, Xing H-C, Bobik E, Wauben I, Auestad N, Montalto M, and Wainwright PE. Effects of y-linolenic acid and docosahexaenoic acid in formulae on brain fatty acid composition in artificially reared rats. Lipids, 34: 1057-1063, (1999). Wainwright PE, Xing H-C, Ward GR, Huang Y-S, Bobik E, Auestad N, and Montalto M. Water maze performance is unaffected in artificially reared rats fed diets supplemented with arachidonic acid and docosahexaenoic acid. Journal of Nutrition, 129: 1079-1089, (1999).Williams CM and Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB<sub>1</sub>) receptors. Psychopharmacology, 143:315-317, (1999). Williams G, Harrold JA, and Cutler DJ. The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box. Proceedings of the Nutritional Society, 59:385-396, (2000). DATE CONSIDERED **EXAMINER**